Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.

This study aims to use convalescent plasma as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit. Donors must have anti-SARS CoV2 antibodies. Recipients must be critically ill Covid-19 patients on mechanical ventilation.

Inclusion Criteria:

• Age: 18 years or more.
• Patient with Covid-19 confirmed with nuclear acid testing
• Critically ill patients with Covid-19 on mechanical ventilation. Potencially critically ill patients (with acute respiratory distress syndrome, septic shock and/or multiple organ failure) with Covid-19.
• Diagnosed with acute respiratory distress syndrome.
• Informed consent.

Exclusion Criteria:

• No consent.
• Symptoms for a period longer than 20 days.
• Not detectable by acid nuclear testing within 48 hours prior to elegibility.
• Descompensated congestive heart failure, in which receiving 500ml of intrasvascular volume signifies a life risk.
• History of severe adverse events or anaphylaxis to plasma components